ArticlebioRxiv : the preprint server for biology2024
Trem2 deficiency attenuates breast cancer tumor growth in lean, but not obese or weight loss, mice and is associated with alterations of clonal T cell populations.
Elysa W Pierro, Matthew A Cottam, Hanbing An, Brian D Lehmann, Jennifer A Pietenpol, Kathryn E Wellen, Liza Makowski, Jeffrey C Rathmell, Barbara Fingleton, Alyssa H Hasty
Abstract readPreprint
In one paragraphArticle in bioRxiv : the preprint server for biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
5 · Who and what moneyAuthors and funding
10 authors.
Elysa W PierroDepartment of Molecular Physiology and Biophysics, Vanderbilt University, Nashville, TN.ORCID 0000-0002-0011-2112 Matthew A CottamDepartment of Surgery, Division of Surgical Oncology and Endocrine Surgery, Vanderbilt University Medical Center, Nashville, TN.ORCID 0000-0003-0619-1605 Hanbing AnDepartment of Otolaryngology, Vanderbilt University Medical Center, Nashville, TN.
Brian D LehmannDepartment of Medicine, Division of Hematology and Oncology, Vanderbilt University Medical Center, Nashville, TN.
Jennifer A PietenpolVanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, TN.ORCID 0000-0001-6268-6798 Kathryn E WellenDepartment of Cancer Biology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA.ORCID 0000-0002-2281-0042 Liza MakowskiDepartment of Medicine, Division of Hematology-Oncology, University of Tennessee Health Science Center, Memphis, TN, 31863, USA.ORCID 0000-0002-5337-8037 Jeffrey C RathmellDepartment of Molecular Physiology and Biophysics, Vanderbilt University, Nashville, TN.ORCID 0000-0002-4106-3396 Barbara FingletonVanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, TN.ORCID 0000-0003-1132-0782 Alyssa H HastyDepartment of Molecular Physiology and Biophysics, Vanderbilt University, Nashville, TN.ORCID 0000-0001-7302-8045 Funding
Tumor Immunology and Microenvironment Research ProgramP30CA068485 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Ben Ho Park · 1995 to 2026
$172.8MTISSUE CoreP50CA098131 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI PARK, BEN HO, PIETENPOL, JENNIFER A · 2003 to 2024
$48.7MVANDERBILT UNIVERSITY CTSA FOR PEDIATRIC RESEARCHUL1RR024975 · NCRR · VANDERBILT UNIVERSITY · PI BERNARD, GORDON RAPHAEL · 2007 to 2011
$45.7MTranslational Analysis CoreP30DK058404 · NIDDK · VANDERBILT UNIVERSITY MEDICAL CENTER · PI MARY Kay WASHINGTON · 2002 to 2026
$29.9MVanderbilt Diabetes Research CenterP30DK020593 · NIDDK · VANDERBILT UNIVERSITY MEDICAL CENTER · PI OWEN P MCGUINNESS · 2012 to 2026
$29.3MShop Module CoreP30EY008126 · NEI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI David J. Calkins · 1989 to 2026
$19.6MVANTAGE:Consolidation to create the Vanderbilt Technologies for Advanced GenomicsG20RR030956 · NCRR · VANDERBILT UNIVERSITY · PI PIETENPOL, JENNIFER A · 2010 to 2010
$8.7MDetermining the contribution of microbial-derived metabolites to protective immunity in obesity-driven cancer risk.U01CA272541 · NCI · UNIVERSITY OF TENNESSEE HEALTH SCI CTR · PI Liza Makowski-Hayes, Joseph F PIERRE · 2022 to 2026
$5.1MRole of microbial-modulated bile acid receptor signaling in breast cancerR01CA253329 · NCI · UNIVERSITY OF TENNESSEE HEALTH SCI CTR · PI Katherine Loree Cook, Liza Makowski-Hayes · 2020 to 2026
$3.0MBLRD Merit Review Research Career Scientist (RCS) Award (IK6)IK6BX005649 · VA · VETERANS HEALTH ADMINISTRATION · PI HASTY, ALYSSA H · 2021 to 2023
–Turnover of Adipose Tissue MacrophagesI01BX002195 · VA · VETERANS HEALTH ADMINISTRATION · PI HASTY, ALYSSA H · 2014 to 2024
–BLRD VA I01 BX002195BLRD VA IK6 BX005649NCI NIH HHS P30 CA068485NCI NIH HHS P50 CA098131NCI NIH HHS R01 CA253329NCI NIH HHS U01 CA272541NCRR NIH HHS G20 RR030956NCRR NIH HHS UL1 RR024975NEI NIH HHS P30 EY008126NIDDK NIH HHS P30 DK020593NIDDK NIH HHS P30 DK058404
6 · The paper itselfAbstract
Obesity is an established risk factor for breast cancer development and worsened prognosis; however, the mechanisms for this association - and the potential benefits of weight loss - have not been fully explored. The adipose environment surrounding breast tumors, which is inflamed in obesity, has been implicated in tumor progression. An emerging therapeutic target for cancer is TREM2, a transmembrane receptor of the immunoglobulin superfamily that is expressed on macrophages in adipose tissue and tumors. We utilized genetic loss of function (
Indexed as
adipose tissuebreast cancermacrophagesobesityT cellsTrem2tumor microenvironmentweight loss
Identifiers
PMID39386686
PMCPMC11463595
What OpenQuestion holds
Textmetadata
LicenceCC BY-ND
Read underepoch 390